» Articles » PMID: 38786229

OnyxGel or Coil Versus Hydrogel As Embolic Agents in Endovascular Applications: Review of the Literature and Case Series

Overview
Journal Gels
Date 2024 May 24
PMID 38786229
Authors
Affiliations
Soon will be listed here.
Abstract

This review focuses on the use of conventional gel or coil and "new" generation hydrogel used as an embolic agent in endovascular applications. In general, embolic agents have deep or multidistrict vascular penetration properties as they ensure complete occlusion of vessels by exploiting the patient's coagulation system, which recognises them as substances foreign to the body, thus triggering the coagulation cascade. This is why they are widely used in the treatment of endovascular corrections (EV repair), arteriovenous malformations (AVM), endoleaks (E), visceral aneurysms or pseudo-aneurysms, and embolisation of pre-surgical or post-surgical (iatrogenic) lesions. Conventional gels such as Onyx or coils are now commercially available, both of which are frequently used in endovascular interventional procedures, as they are minimally invasive and have numerous advantages over conventional open repair (OR) surgery. Recently, these agents have been modified and optimised to develop new embolic substances in the form of hydrogels based on alginate, chitosan, fibroin and other polymers to ensure embolisation through phase transition phenomena. The main aim of this work was to expand on the data already known in the literature concerning the application of these devices in the endovascular field, focusing on the advantages, disadvantages and safety profiles of conventional and innovative embolic agents and also through some clinical cases reported. The clinical case series concerns the correction and exclusion of endoleak type I or type II appeared after an endovascular procedure of exclusion of aneurysmal abdominal aortic (EVAR) with a coil (coil penumbra released by a LANTERN microcatheter), the exclusion of renal arterial malformation (MAV) with a coil (penumbra coil released by a LANTERN microcatheter) and the correction of endoleak through the application of Onyx 18 in the arteries where sealing by the endoprosthesis was not guaranteed.

References
1.
Abdeltawab H, Svirskis D, Sharma M . Formulation strategies to modulate drug release from poloxamer based in situ gelling systems. Expert Opin Drug Deliv. 2020; 17(4):495-509. DOI: 10.1080/17425247.2020.1731469. View

2.
Oliva N, Conde J, Wang K, Artzi N . Designing Hydrogels for On-Demand Therapy. Acc Chem Res. 2017; 50(4):669-679. PMC: 6527116. DOI: 10.1021/acs.accounts.6b00536. View

3.
Li X, Ullah M, Li B, Chen H . Recent Progress in Advanced Hydrogel-Based Embolic Agents: From Rational Design Strategies to Improved Endovascular Embolization. Adv Healthc Mater. 2023; 12(17):e2202787. DOI: 10.1002/adhm.202202787. View

4.
Liu J, Yang S, Li X, Yan Q, Reaney M, Jiang Z . Alginate Oligosaccharides: Production, Biological Activities, and Potential Applications. Compr Rev Food Sci Food Saf. 2020; 18(6):1859-1881. DOI: 10.1111/1541-4337.12494. View

5.
Chun J, Morgan R . Transcatheter embolisation of type 1 endoleaks after endovascular aortic aneurysm repair with Onyx: when no other treatment option is feasible. Eur J Vasc Endovasc Surg. 2013; 45(2):141-4. DOI: 10.1016/j.ejvs.2012.11.010. View